131 related articles for article (PubMed ID: 18996360)
1. Promoter polymorphisms which modulate insulin degrading enzyme expression may increase susceptibility to Alzheimer's disease.
Zuo X; Jia J
Brain Res; 2009 Jan; 1249():1-8. PubMed ID: 18996360
[TBL] [Abstract][Full Text] [Related]
2. Promoter polymorphisms which modulate APP expression may increase susceptibility to Alzheimer's disease.
Lv H; Jia L; Jia J
Neurobiol Aging; 2008 Feb; 29(2):194-202. PubMed ID: 17112637
[TBL] [Abstract][Full Text] [Related]
3. Association between promoter polymorphisms of vascular endothelial growth factor gene and sporadic Alzheimer's disease among Northern Chinese Han.
Yuan Q; Zuo X; Jia J
Neurosci Lett; 2009 Jul; 457(3):133-6. PubMed ID: 19429179
[TBL] [Abstract][Full Text] [Related]
4. Sequence variants of IDE are associated with the extent of beta-amyloid deposition in the Alzheimer's disease brain.
Blomqvist ME; Chalmers K; Andreasen N; Bogdanovic N; Wilcock GK; Cairns NJ; Feuk L; Brookes AJ; Love S; Blennow K; Kehoe PG; Prince JA
Neurobiol Aging; 2005 Jun; 26(6):795-802. PubMed ID: 15718037
[TBL] [Abstract][Full Text] [Related]
5. Alternative splicing of human insulin-degrading enzyme yields a novel isoform with a decreased ability to degrade insulin and amyloid beta-protein.
Farris W; Leissring MA; Hemming ML; Chang AY; Selkoe DJ
Biochemistry; 2005 May; 44(17):6513-25. PubMed ID: 15850385
[TBL] [Abstract][Full Text] [Related]
6. Evidence for genetic linkage of Alzheimer's disease to chromosome 10q.
Bertram L; Blacker D; Mullin K; Keeney D; Jones J; Basu S; Yhu S; McInnis MG; Go RC; Vekrellis K; Selkoe DJ; Saunders AJ; Tanzi RE
Science; 2000 Dec; 290(5500):2302-3. PubMed ID: 11125142
[TBL] [Abstract][Full Text] [Related]
7. PPARgamma transcriptionally regulates the expression of insulin-degrading enzyme in primary neurons.
Du J; Zhang L; Liu S; Zhang C; Huang X; Li J; Zhao N; Wang Z
Biochem Biophys Res Commun; 2009 Jun; 383(4):485-90. PubMed ID: 19383491
[TBL] [Abstract][Full Text] [Related]
8. Lack of association between IDE genetic variability and Down's syndrome.
Arpino C; Piciullo A; Palmarino M; Saccucci P; Galasso C; Lucarelli P; Curatolo P
Neurosci Lett; 2005 Jul 1-8; 382(1-2):93-5. PubMed ID: 15911128
[TBL] [Abstract][Full Text] [Related]
9. Weak independent association signals between IDE polymorphisms, Alzheimer's disease and cognitive measures.
Mueller JC; Riemenschneider M; Schoepfer-Wendels A; Gohlke H; Konta L; Friedrich P; Illig T; Laws SM; Förstl H; Kurz A
Neurobiol Aging; 2007 May; 28(5):727-34. PubMed ID: 16675064
[TBL] [Abstract][Full Text] [Related]
10. Lack of association of 5 SNPs in the vicinity of the insulin-degrading enzyme (IDE) gene with late-onset Alzheimer's disease.
Ozturk A; DeKosky ST; Kamboh MI
Neurosci Lett; 2006 Oct; 406(3):265-9. PubMed ID: 16914266
[TBL] [Abstract][Full Text] [Related]
11. Promoter polymorphisms which regulate ADAM9 transcription are protective against sporadic Alzheimer's disease.
Cong L; Jia J
Neurobiol Aging; 2011 Jan; 32(1):54-62. PubMed ID: 19237226
[TBL] [Abstract][Full Text] [Related]
12. MMP-2, -3 and -9 levels and activity are not related to Abeta load in the frontal cortex in Alzheimer's disease.
Baig S; Kehoe PG; Love S
Neuropathol Appl Neurobiol; 2008 Apr; 34(2):205-15. PubMed ID: 17971072
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-18 promoter polymorphisms and risk of late onset Alzheimer's disease.
Yu JT; Tan L; Song JH; Sun YP; Chen W; Miao D; Tian Y
Brain Res; 2009 Feb; 1253():169-75. PubMed ID: 19073159
[TBL] [Abstract][Full Text] [Related]
14. Insulin-degrading enzyme is genetically associated with Alzheimer's disease in the Finnish population.
Vepsäläinen S; Parkinson M; Helisalmi S; Mannermaa A; Soininen H; Tanzi RE; Bertram L; Hiltunen M
J Med Genet; 2007 Sep; 44(9):606-8. PubMed ID: 17496198
[TBL] [Abstract][Full Text] [Related]
15. Positive association between risk for late-onset Alzheimer disease and genetic variation in IDE.
Björk BF; Katzov H; Kehoe P; Fratiglioni L; Winblad B; Prince JA; Graff C
Neurobiol Aging; 2007 Sep; 28(9):1374-80. PubMed ID: 16876916
[TBL] [Abstract][Full Text] [Related]
16. Insulin-degrading enzyme antagonizes insulin-dependent tissue growth and Abeta-induced neurotoxicity in Drosophila.
Tsuda M; Kobayashi T; Matsuo T; Aigaki T
FEBS Lett; 2010 Jul; 584(13):2916-20. PubMed ID: 20493190
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of the insulin degrading enzyme polymorphisms and susceptibility to Alzheimer's disease.
Zhang Y; Wang B; Wan H; Zhou Q; Li T
Neurosci Lett; 2013 Apr; 541():132-7. PubMed ID: 23416320
[TBL] [Abstract][Full Text] [Related]
18. Insulin degrading enzyme activity selectively decreases in the hippocampal formation of cases at high risk to develop Alzheimer's disease.
Zhao Z; Xiang Z; Haroutunian V; Buxbaum JD; Stetka B; Pasinetti GM
Neurobiol Aging; 2007 Jun; 28(6):824-30. PubMed ID: 16769157
[TBL] [Abstract][Full Text] [Related]
19. [Cerebral proteolysis of amiloid-b peptide: relevance of insulin-degrading enzyme in Alzheimer's disease].
Leal MC; Fernandez Gamba A; Morelli L; Castaño EM
Medicina (B Aires); 2009; 69(4):466-72. PubMed ID: 19770104
[TBL] [Abstract][Full Text] [Related]
20. Nitric oxide inhibits insulin-degrading enzyme activity and function through S-nitrosylation.
Cordes CM; Bennett RG; Siford GL; Hamel FG
Biochem Pharmacol; 2009 Mar; 77(6):1064-73. PubMed ID: 19154729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
